Combination Treatment Options for Castration-Resistant Prostate Cancer

Article Sidebar

Open access book Prostate Cancer cover
PDF HTML XML
Published: May 27, 2021
DOI: https://doi.org/10.36255/exonpublications.prostatecancer.combinationtreatment.2021
Keywords:
androgen deprivation therapy, castration-resistant prostate cancer, chemotherapy, combination treatment, immunotherapy

Main Article Content

Dannah R. Miller, PHD
Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Matthew A. Ingersoll, PHD
Department of Pharmacology, Creighton University, Omaha, NE, USA
Benjamin A. Teply, MD
Division of Hematology/Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA
Ming-Fong Lin, PHD
Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA

ABSTRACT


Prostate cancer is the most commonly diagnosed solid tumor and the second leading cause of cancer-related deaths in men in the United States. While localized prostate cancer has an excellent prognosis for patients, about one-third of patients are diagnosed with high-risk disease, including metastatic cancer. The 5-year survival rate of metastatic prostate cancer is only about 30%. Due to the androgen dependence of prostate cancer cells, androgen-deprivation therapy is the standard of care for metastatic prostate cancer, which includes both surgical and medical approaches. Nevertheless, androgen-deprivation therapy in general is not curative; patients can develop castration-resistant prostate cancer. Despite current chemotherapies, including the utilization of novel androgen signaling inhibitors and immunotherapy, patients still succumb to the disease. Hence, castration-resistant prostate cancer is a lethal disease. Combination treatment is a strategy for treating this lethal disease and thus will be the focus of discussion in this chapter.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

Book
Prostate Cancer
Section
Chapter 5
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.